• 7/5/2007
  • New York, NY
  • staff
  • Forbes.com

Sanofi-Aventis said its Taxotere drug has been accepted by the US Food and Drug Administration (FDA) for filing and assigned priority review status for the treatment of head and neck cancer prior to chemoradiotherapy and surgery.

In a statement, Sanofi-Aventis explained FDA grants priority review status to products that, if approved, would be a significant improvement on existing market products.

To date, Sanofi said, Taxotere has received a total of seven indications in the US.

Taxotere is the fourth best-selling drug for Sanofi-Aventis. It is currently used to treat breast cancer and non-small cell lung cancer as well as prostate cancer.

At the start of June, the French drugs company also said Japanese regulators will consider on a priority basis the approval of its Taxotere anti-cancer drug for use in prostate cancer.